271 related articles for article (PubMed ID: 17915620)
1. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K
Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620
[TBL] [Abstract][Full Text] [Related]
2. Remission of nephrotic syndrome after removal of localized Castleman's disease.
Keven K; Nergizoğlu G; Ateş K; Erekul S; Orhan D; Ertürk S; Tulunay O; Karatan O; Ertuğ AE
Am J Kidney Dis; 2000 Jun; 35(6):1207-11. PubMed ID: 10845836
[TBL] [Abstract][Full Text] [Related]
3. A long-term remission of renal amyloidosis with nephrotic syndrome after autologous peripheral blood stem-cell transplantation.
Ogawa K; Ikeda K; Furukawa M; Harada-Shirado K; Mashimo Y; Takahashi H; Matsumoto H; Kimura S; Shichishima-Nakamura A; Ohkawara H; Hashimoto Y; Asahi K; Noji H; Ohto H; Takeishi Y
Fukushima J Med Sci; 2010 Dec; 56(2):151-6. PubMed ID: 21502717
[TBL] [Abstract][Full Text] [Related]
4. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of nephrotic syndrome due to systemic AL amyloidosis after autologous stem cell transplantation: renal response is an important therapeutic end point.
Akay OM; Sahin G; Kabukcuoglu S; Yalcin AU; Gulbas Z
Clin Nephrol; 2008 Apr; 69(4):294-7. PubMed ID: 18397705
[TBL] [Abstract][Full Text] [Related]
6. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T
Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172
[TBL] [Abstract][Full Text] [Related]
8. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
[TBL] [Abstract][Full Text] [Related]
9. Primary amyloidosis of the kidney.
Shafique S; Wetmore J; Almehmi A
W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
[TBL] [Abstract][Full Text] [Related]
10. [Nephrotic Syndrome Caused by AA Amyloidosis Secondary to Unicentric Castleman's Disease:Report of One Case].
You RL; Wen YB; Wang J; Ma J; Chen LM; Li XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Jun; 44(3):540-544. PubMed ID: 35791957
[TBL] [Abstract][Full Text] [Related]
11. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
[TBL] [Abstract][Full Text] [Related]
12. [White blood cell lysis syndrome after autologous peripheral blood stem cell transplantation in the treatment of renal AL amyloidosis. Case report].
Gatica A; Bertin P; Tagle R
Rev Med Chil; 2006 Jun; 134(6):763-6. PubMed ID: 17130952
[TBL] [Abstract][Full Text] [Related]
13. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
[TBL] [Abstract][Full Text] [Related]
14. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
[TBL] [Abstract][Full Text] [Related]
15. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
16. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease.
Perfetti V; Bellotti V; Maggi A; Arbustini E; De Benedetti F; Paulli M; Marinone MG; Merlini G
Am J Hematol; 1994 Jul; 46(3):189-93. PubMed ID: 7910717
[TBL] [Abstract][Full Text] [Related]
17. Secondary amyloidosis associated with Castleman's disease.
Tanaka K; Horita M; Shibayama H; Seike M; Itoh Y; Hamaguchi K; Sato Y; Sakata T; Ishida T
Intern Med; 1995 Feb; 34(2):122-6. PubMed ID: 7727877
[TBL] [Abstract][Full Text] [Related]
18. Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement.
Gertz MA; Leung N; Lacy MQ; Dispenzieri A
Kidney Int; 2005 Oct; 68(4):1464-71. PubMed ID: 16164623
[TBL] [Abstract][Full Text] [Related]
19. Castleman's disease with renal amyloidosis and nephrotic syndrome.
Arinsoy T; Yilmaz M; Ataoğlu O; Bali M; Sindel S
Nephrol Dial Transplant; 1997 Dec; 12(12):2713-6. PubMed ID: 9430878
[No Abstract] [Full Text] [Related]
20. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
